Cancer Family
Female Reproductive System Adnexal Neoplasm
CI-CAN-00000180Explore in graph →
Non-malignant765 active trials5 approved drugs94 evidence items
- NCIt
- C212117
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000180Explore in graph →
Clinical trials
3,476 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01272817 | Nonmyeloablative Allogeneic Transplant(Mini-allo) | completed | N/A | 36 | Scripps HealthOTHER | 1 | Nov 23, 2022 | clinicaltrials |
| NCT03811899 | 18F-DCFPyL PET/CT in High-grade Epithelial Ovarian Cancer (PET HOC) | completed | N/A | 20 | University Health Network, TorontoOTHER | 1 | Nov 2, 2022 | clinicaltrials |
| NCT01097746 |
| First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer |
| completed |
| Phase 2 |
| 33 |
| M.D. Anderson Cancer CenterOTHER |
| 1 |
| Oct 28, 2022 |
| clinicaltrials |
| NCT00623831 | A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen | completed | Phase 1 | 17 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT05011539 | Thiol-disulfide Homeostasis in Patients With Ovarian Cancer | completed | — | 115 | Tepecik Training and Research HospitalOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT02133703 | Decision Support Following Genetic Testing for Breast-Ovarian Cancer Susceptibility | completed | N/A | 369 | Georgetown UniversityOTHER | 1 | Oct 14, 2022 | clinicaltrials |
| NCT00616941 | Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 | 28 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT01975831 | A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab | completed | Phase 1 | 104 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT03857087 | 68Ga-PSMA PET in Diagnosing Metastasis in Patients With Ovarian Cancer | completed | — | 7 | University of California, San FranciscoOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT02431559 | Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer | completed | Phase 1 / Phase 2 | 53 | Ludwig Institute for Cancer ResearchOTHER | 2 | Oct 10, 2022 | clinicaltrials |
| NCT02440425 | Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer | completed | Phase 2 | 42 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 7, 2022 | clinicaltrials |
| NCT03106987 | A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer.(OReO) | completed | Phase 3 | 220 | AstraZenecaINDUSTRY | 11 | Oct 7, 2022 | clinicaltrials |
| NCT01821833 | Omega-3 Fatty Acid in Treating Pain in Patients With Breast or Ovarian Cancer Receiving Paclitaxel | completed | N/A | 60 | New Mexico Cancer Research AllianceOTHER | 1 | Oct 5, 2022 | clinicaltrials |
| NCT05564234 | Role of Laparoscopy in Assessing Resectability of Ovarian Cancer | completed | N/A | 30 | Zagazig UniversityOTHER_GOV | 1 | Oct 4, 2022 | clinicaltrials |
| NCT05553067 | Oncogenic Role of Engrailed (EN)-2 in Epithelial Ovarian Neoplasms | completed | — | 100 | Sohag UniversityOTHER | 1 | Sep 27, 2022 | clinicaltrials |
| NCT04352439 | Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy | completed | Phase 4 | 19 | Duke UniversityOTHER | 1 | Sep 26, 2022 | clinicaltrials |
| NCT03470805 | Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma | completed | Phase 2 | 9 | Grupo Español de Investigación en Cáncer de OvarioOTHER | 1 | Sep 23, 2022 | clinicaltrials |
| NCT02788708 | Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer | completed | Phase 1 | 26 | Floor BackesOTHER | 1 | Sep 19, 2022 | clinicaltrials |
| NCT02354586 | A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens(QUADRA) | completed | Phase 2 | 463 | Tesaro, Inc.INDUSTRY | 2 | Sep 15, 2022 | clinicaltrials |
| NCT02865811 | Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer | completed | Phase 2 | 26 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 13, 2022 | clinicaltrials |
| NCT02307500 | Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy(RESOUND) | completed | Phase 2 | 82 | Istituto Clinico HumanitasOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT03056833 | Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer | completed | Phase 1 | 35 | Ronald BuckanovichOTHER | 1 | Sep 7, 2022 | clinicaltrials |
| NCT02518256 | Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma - Study of Sensitivity and Specificity(LUDOC II) | completed | N/A | 270 | Medical University of ViennaOTHER | 4 | Sep 6, 2022 | clinicaltrials |
| NCT02039388 | Lavage of the Uterine Cavity for the Diagnosis of Serous Tubal Intraepithelial Carcinoma(LUSTIC) | completed | N/A | 701 | Medical University of ViennaOTHER | 8 | Sep 2, 2022 | clinicaltrials |
| NCT04823871 | Early Detection of High Grade Ovarian Cancer Using Uterine Lavage EHUD Study and Duplex Sequencing(EHUD) | completed | N/A | 406 | Paul Speiser, Prof.MD,OTHER | 4 | Sep 2, 2022 | clinicaltrials |
| NCT03662204 | Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors | completed | — | 5,133 | Exact Sciences CorporationINDUSTRY | 1 | Sep 1, 2022 | clinicaltrials |
| NCT02354131 | Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer(AVANOVA) | completed | Phase 1 / Phase 2 | 108 | Nordic Society of Gynaecological Oncology - Clinical Trials UnitOTHER | 2 | Aug 30, 2022 | clinicaltrials |
| NCT04392102 | A Study of Niraparib in Patients With Relapsed Ovarian Cancer | completed | Phase 2 | 15 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 1 | Aug 29, 2022 | clinicaltrials |
| NCT04334239 | Effectiveness of Care in Certified Cancer Centres in Germany(WiZen) | completed | — | 670,000 | Technische Universität DresdenOTHER | 1 | Aug 23, 2022 | clinicaltrials |
| NCT05512676 | Trabectedin/Caelyx vs Cisplatin Hypersensitivity in Relapsed Ovarian Cancer Patients Allergic to Platinum(TvsCH) | completed | — | 40 | Oslo University HospitalOTHER | 0 | Aug 23, 2022 | clinicaltrials |
| NCT03414047 | A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer | completed | Phase 2 | 172 | Eli Lilly and CompanyINDUSTRY | 8 | Aug 19, 2022 | clinicaltrials |
| NCT03604653 | Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal Cancers | completed | — | 10 | Holy Name Medical Center, Inc.OTHER | 1 | Aug 3, 2022 | clinicaltrials |
| NCT02477644 | Platine, Avastin and OLAparib in 1st Line(PAOLA-1) | completed | Phase 3 | 806 | Arcagy ResearchOTHER | 11 | Aug 2, 2022 | clinicaltrials |
| NCT01673217 | Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer | completed | Phase 1 | 18 | Roswell Park Cancer InstituteOTHER | 1 | Aug 1, 2022 | clinicaltrials |
| NCT04545632 | Docetaxel Ethanol-induced Symptoms; The Incidence and Risk Forecating Factor(DETECT) | completed | — | 458 | Boryung Pharmaceutical Co., LtdINDUSTRY | 1 | Jul 27, 2022 | clinicaltrials |
| NCT05476341 | A Phase I Clinical Trial of Bevacizumab Injection | completed | Phase 1 | 98 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 27, 2022 | clinicaltrials |
| NCT03029598 | Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | 29 | University of WashingtonOTHER | 1 | Jul 26, 2022 | clinicaltrials |
| NCT01896778 | Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer | completed | N/A | 9 | Roswell Park Cancer InstituteOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT01462890 | Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer(BOOST) | completed | Phase 3 | 927 | AGO Study GroupOTHER | 6 | Jul 20, 2022 | clinicaltrials |
| NCT01809379 | Intraperitoneal Aerosol High-pressure Chemotherapy for Women With Recurrent Ovarian Cancer | completed | Phase 2 | 69 | Ruhr University of BochumOTHER | 1 | Jul 8, 2022 | clinicaltrials |
| NCT02475772 | A Study With Intraperitoneal Cisplatin and Doxorubicin in Recurrent Ovarian Cancer and Peritoneal Carcinomatosis | completed | Phase 1 | 15 | Clemens TempferOTHER | 1 | Jul 8, 2022 | clinicaltrials |
| NCT05448586 | Opioid Free Anaesthesia in Oncologic Gynaecological Surgery: Is There Any Benefit? | completed | — | 132 | Instituto de Investigación Hospital Universitario La PazOTHER | 1 | Jul 7, 2022 | clinicaltrials |
| NCT03562897 | Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer | completed | Phase 2 | 40 | Catalysis SLINDUSTRY | 1 | Jul 6, 2022 | clinicaltrials |
| NCT03075462 | A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients | completed | Phase 1 | 98 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 1, 2022 | clinicaltrials |
| NCT03509636 | A Study of Fluzoparib（SHR-3162）in BRCA1/2-mutant Relapsed Ovarian Cancer | completed | Phase 1 | 113 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 1, 2022 | clinicaltrials |
| NCT00976911 | AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer | completed | Phase 3 | 361 | Hoffmann-La RocheINDUSTRY | 14 | Jun 21, 2022 | clinicaltrials |
| NCT02317705 | Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer | completed | Phase 2 | 48 | On Target Laboratories, LLCINDUSTRY | 1 | Jun 21, 2022 | clinicaltrials |
| NCT04630327 | Validation of the Russian and Kazakh Versions of the Beck Depression Inventory and Beck Anxiety Inventory | completed | — | 226 | Kazakh Medical University of Continuing EducationOTHER | 1 | Jun 21, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Nov 23, 2022source: clinicaltrials